Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...
Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh ...
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to ...
Hosted on MSN5h
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowGilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...
Global biopharmaceutical company Gilead Sciences Inc. (Nasdaq: GILD) is closing its office in Seattle and laying off 72 ...
(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...
Data shows Latino and Black people make up nearly 30% of the Bay Area population but only about 10% of active medical ...
FOSTER CITY, Calif., November 14, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback